Skip to content
AnalystLens

Teva Pharmaceutical Industries 8-K Report, Financial Results (May 7, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 7, 2025
Period End
May 7, 2025
Security
TEVA
In the record · 2016–202610-K1110-Q278-K283

TEVA filed 11 annual reports (10-K), 27 quarterly reports (10-Q) and 283 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’19Nov ’19
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported first-quarter 2025 results for the period ended March 31, 2025, furnished under Item 2.02 of this Form 8-K as Exhibit 99.1.

Revenues were $3,891 milliona, up 2% in U.S. dollars and 5% in local currency, and the company described this as its ninth consecutive quarter of revenue growth excluding Sanofi collaboration revenues. GAAP operating income was $519 million versus an operating loss of $218 million a year earlier, while non-GAAP operating income was $946 million, a 24.3% non-GAAP operating margin. GAAP diluted EPS was $0.18 and non-GAAP diluted EPS was $0.52, compared with $0.48 in the prior-year quarter.

Cash flow used in operating activities was $105 millionb and free cash flow was $107 million. Total debt fell to $16,651 million from $17,783 million at December 31, 2024, mainly due to repayment at maturity of $1,368 million of senior notes. The company revised its 2025 outlook: non-GAAP diluted EPS is now $2.45 to $2.65, and the AUSTEDO revenue outlook was raised to $1.95 to $2.05 billion.

The revised outlook excludes contributions from the Japan business venture, which was divested on March 31, 2025, and from Sanofi development milestone payments tied to duvakitug. Teva also said it expects roughly $700 millionc of net savings by 2027 and continues to pursue a sale of its API business, which is classified as held for sale. Segment results were mixed.

United States segment profit rose 52% to $532 milliond on higher AUSTEDO sales and a gross margin of 55.4%. Europe segment profit fell 22% to $329 million, and International Markets profit fell 17% to $97 million. The filing notes that current U.S. tariffs are expected to have an immaterial impact and are absorbed in the updated outlook.

02—Key points

Key Highlights

  1. Q1 2025 revenues of $3.9 billion, up 5% in local currency and 2% in U.S. dollars after a $101 million foreign exchange impact
  2. GAAP diluted EPS of $0.18 and non-GAAP diluted EPS of $0.52, up $0.04 or 8% year over year
  3. AUSTEDO worldwide revenues of $411 million, up 39% in local currency; full-year 2025 AUSTEDO outlook raised to $1.95-2.05 billion
  4. Non-GAAP diluted EPS outlook for 2025 raised to $2.45-2.65 from $2.35-2.65 in the January outlook, with Adjusted EBITDA of $4.7-5.0 billion
  5. Debt reduced to $16,651 million from $17,783 million after $1,368 million of senior notes were repaid at maturity
  6. Free cash flow of $107 million in Q1 2025, and full-year 2025 free cash flow outlook of $1.6-1.9 billion unchanged
  7. Japan business venture divested March 31, 2025; API business classified as held for sale and sale being pursued

03—Questions

Frequently Asked Questions

  1. Why did Teva revise its 2025 outlook?

    The filing says the revision reflects an underlying increase in the full-year outlook, excluding the impact of the Japan business venture divestiture that closed March 31, 2025. The revised outlook raised non-GAAP operating income at the low end by $200 million, and non-GAAP diluted EPS at the low end by $0.10. It also reflects a $200 million revenue reduction at the high end of the range.

  2. What drove the improvement in profitability in the first quarter?

    The filing attributes the higher gross profit margin, which rose to 48.2% GAAP and 52.8% non-GAAP, mainly to a favorable product mix driven by higher AUSTEDO revenues. GAAP operating income improved to $519 million from an operating loss of $218 million a year earlier, which had included impairments and restructuring charges.

  3. How did Teva's segments perform?

    United States segment profit rose 52% to $532 million, driven by higher gross profit. Europe segment profit fell 22% to $329 million on lower gross profit, and International Markets segment profit fell 17% to $97 million, mainly due to lower gross profit.

  4. What are the company's main strategic priorities?

    Teva is in the Acceleration phase of its Pivot to Growth strategy. Priorities include growing its innovative portfolio, including AUSTEDO, AJOVY and UZEDY, advancing duvakitug toward Phase 3 with program initiation expected in H2 2025, preparing an olanzapine LAI NDA submission in H2 2025, and targeting a 30% operating margin in 2027 through about $700 million of net savings.

04—Continue

← View all 8-K filings